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Review Article
Benign Prostatic Hyperplasia: from Bench to Clinic
Tag Keun Yoo, Hee Ju Cho
Department of Urology, Eulji University School of Medicine, Seoul, Korea
Benign prostatic hyperplasia (BPH) is a prevalent disease, especially in old men, and 
often results in lower urinary tract symptoms (LUTS). This chronic disease has im-
portant care implications and financial risks to the health care system. LUTS are 
caused not only by mechanical prostatic obstruction but also by the dynamic component 
of obstruction. The exact etiology of BPH and its consequences, benign prostatic en-
largement and benign prostatic obstruction, are not identified. Various theories con-
cerning the causes of benign prostate enlargement and LUTS, such as metabolic syn-
drome, inflammation, growth factors, androgen receptor, epithelial-stromal inter-
action, and lifestyle, are discussed. Incomplete overlap of prostatic enlargement with 
symptoms and obstruction encourages focus on symptoms rather than prostate en-
largement and the shifting from surgery to medicine as the treatment of BPH. Several 
alpha antagonists, including alfuzosin, doxazosin, tamsulosin, and terazosin, have 
shown excellent efficacy without severe adverse effects. In addition, new alpha antago-
nists, silodosin and naftopidil, and phosphodiesterase 5 inhibitors are emerging as BPH 
treatments. In surgical treatment, laser surgery such as photoselective vaporization 
of the prostate and holmium laser prostatectomy have been introduced to reduce com-
plications and are used as alternatives to transurethral resection of the prostate 
(TURP) and open prostatectomy. The status of TURP as the gold standard treatment 
of BPH is still evolving. We review several preclinical and clinical studies about the 
etiology of BPH and treatment options.
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is one of the most com-
mon diseases, and its incidence has accelerated recently. 
BPH usually occurs in men in their 50s, and 80% of men 
in their 70s suffer from BPH-related lower urinary tract 
symptoms (LUTS) [1]. Although BPH is not a fatal disease, 
the morbidity from BPH and its potential risk of complica-
tions diminishes quality of life (QoL) and causes huge social 
financial problems [2,3]. BPH-related LUTS are a con-
sequence of dynamic and static obstruction. In the past, 
age, genetics, and testosterone were regarded as the pri-
mary causes of prostate enlargement, but recently, food, 
exercise, lifestyle, and metabolic syndrome have been rec-
ognized as other major causes of BPH and have been widely 
researched [4]. There have been many changes in the treat-
ment pattern of BPH. Alpha-blockers and 5-alpha reduc-
tase inhibitors are becoming the first-line treatment option 
owing to their excellent efficacy and convenience of admin-
istering without severe adverse effects. Laser surgery as 
a substitute for previous BPH surgery such as transure-
thral resection of the prostate (TURP) and open prostatec-
tomy has also been attempted. Several research studies on 
etiologies and treatment options have been published from 
various preclinical and clinical aspects. This article pres-
ents the scientific foundation of prostate enlargement and 
some reports about innovative trials of BPH therapy.Korean J Urol 2012;53:139-148
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ETIOLOGY
Age and the presence of androgens are established factors 
associated with BPH, but the exact cause of BPH is 
unknown. Previous studies have focused on the links of 
BPH-related LUTS with inflammation, stromal-epithelial 
interaction, and the role of androgen receptors. Various 
etiological models of BPH have recently been evolving 
rapidly. 
1. Metabolic syndrome
In the 1980s, several studies showed that insulin resist-
ance caused various compensatory endocrine aberrations. 
Increased serum insulin levels, one of the major endocrine 
aberrations, are associated with type 2 diabetes, coronary 
disease, hypertension, and dyslipidemia. To date, this clus-
ter of disorders is named the metabolic syndrome (MetS) 
[5,6]. Metabolic syndrome is increasing in countries with 
Western lifestyles, and the prevalence of MetS is around 
34 to 39% in the United States [7]. An pattern of increasing 
prostate volume in patients with type 2 diabetes was re-
ported [8], and the possibility of association between MetS 
and BPH has been investigated in the past decades in sev-
eral studies [8,9]. Of those studies of MetS, 19 of 22 estab-
lished aspects of MetS that are indicated as risk factors of 
BPH. Increased fasting plasma insulin level, increased 
body weight, type 2 diabetes, increased body mass index, 
treated hypertension, and lower high-density lipoprotein 
cholesterol were confirmed to be risk factors of prostate en-
largement, and patients with MetS had a higher annual 
growth rate of the prostate [10-12]. Vikram et al. [13] re-
ported overgrowth of prostate volume in hyperinsulinemic 
rats induced by a high-fat diet, and a reduction of the fast-
ing plasma insulin level caused shrinkage of prostate 
volume. The hypothetical link between hyperinsulinemia 
and BPH was suggested as follows: an increased insulin 
level, a compensatory phenomenon by insulin resistance, 
causes an increased density of growth hormone receptors 
in the liver and then results in an increased hepatic pro-
duction of insulin-like growth factor 1, which promotes the 
proliferation of prostate cells [14,15].
Hyperinsulinemia is correlated with enhanced glucose 
metabolism in the ventromedial hypothalamic neuron, 
which causes increased sympathetic activity of smooth 
muscle contraction in the prostate and bladder neck, which 
increase LUTS [16]. In an animal model, increased sym-
pathetic tone was positively correlated with the increased 
growth rate of the prostate [17], and elevated C-reactive 
protein (CRP) in MetS also decreased nitric oxide (NO) syn-
thesis in endothelial cells. Diminished NO and NO syn-
thesis activity may lead to increased smooth muscle pro-
liferation and prostatic enlargement [18,19].
2. Lifestyle, food, and exercise
In past research, the effect of food on prostate enlargement 
has been controversial. According to a study that analyzed 
data from the placebo arm in the Prostate Cancer 
Prevention Trial (PCPT), which enrolled 18,880 men aged 
over 50 years, high consumption of red meat and a high-fat 
diet was suggested to raise the risk of BPH, and high con-
sumption of vegetables was associated with a reduced risk 
of BPH. Lycopene and supplementation with vitamin D 
could lower the risk of prostate enlargement, but vitamin 
C, vitamin E, and selenium were reported as not being re-
lated [20]. Physical activities were also shown to reduce the 
possibility of prostate enlargement, LUTS, and LUTS-re-
lated surgery [21]. In a meta-analysis that enrolled 43,083 
male patients, intensity of exercise was related to reduc-
tion of risk of prostate enlargement [22]. A negative correla-
tion between the intake of alcohol and prostate enlarge-
ment has been shown in many research studies. In the 
Prostate, Lung, Colorectal and Ovarian Cancer Screening 
Trial, the protective effects of alcohol were noted, partic-
ularly for beer and liquor consumption. Men who consumed 
alcohol moderately were 30% less likely to have clinical 
BPH, 40% less likely to undergo TURP, and 20% less likely 
to have nocturia [23]. However, in a meta-analysis of the 
last 19 studies, incorporating 120,091 patients, men who 
consumed 35 g or more of alcohol per day had a 35% de-
creased risk of BPH but an increased risk of LUTS com-
pared with men who did not consume alcohol [24].
3. Inflammation
Among patients enrolled in the Reduction by Dutasteride 
of Prostate Cancer Event study, histologic inflammation 
was shown in more than 78% men and the severity of LUTS 
and the intensity of inflammation were related [25,26]. 
Another study that enrolled 3,942 patients with BPH 
showed that 43% of patients had histologic inflammation 
and 69% of them had chronic inflammation. Also, in-
flammation in the prostate increased significantly with the 
increase in prostate volume and age [27]. The data from the 
placebo arm of the PCPT demonstrated that elevated CRP 
and interleukin-6 (IL-6) concentrations may increase the 
risk of BPH [28]. A number of inflammatory cells and proin-
flammatory cytokines may be involved in the proliferation 
of the prostate. Kramer et al. [29] concluded that T-lympho-
cytes, B-lymphocytes, and macrophages are chronically ac-
tivated in BPH and produce IL 2, interferon gamma (IFN 
γ), and transforming growth factor β (TGF β), which result 
in fibromuscular growth of the prostate. Proinflammatory 
cytokines released from adjacent inflammatory cells were 
shown to induce the expression of cyclooxygenase-2 
(COX-2) in epithelial cells, which then elevated the pro-
liferation rate of cells in the prostate. In 79% of patients 
with BPH, IL-17 produced by activated T-cells was in-
creased and this overexpression of IL-17 could play a role 
in increasing COX 2 expression [30,31]. In a report by 
Penna et al. [32], human prostate stromal cells were shown 
to act as antigen presenting cells, activating alloanti-
gen-specific CD4
+ T cells to produce IFN-γ and IL-17.
Local hypoxia can play a role as one of the inflammatory 
mediators by inducing lower levels of reactive oxygen spe-
cies, which can promote neovascularization and fibro-Korean J Urol 2012;53:139-148
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TABLE 1. Treatment options for benign prostatic hyperplasia
Watchful waiting
Nonsurgical treatment
Surgical treatment
Medical treatment
Minimally invasive & endoscopic surgery
Laser surgery
Invasive surgery
Alpha-adrenergic blockers
5-Alpha reductase inhibitor
Phosphodiesterase 5 inhibitors
Aromatase inhibitors
Plant extracts (phytotherapy)
Combination of these agents
Transurethral resection of the prostate
Transurethral needle ablation of the prostate
Transurethral microwave therapy of the prostate
Transurethral incision of the prostate
Intraprostatic stents
Vaporization of the prostate
Enucleation of the prostate
Open simple prostatectomy
Laparoscopic simple prostatectomy
blasts to myofibroblast transdifferentiation. In particular, 
increased secretion of vascular endothelial growth factors 
fibroblast growth factors, fibroblast growth factor FGF-7, 
TGF-β, FGF-2, and IL-8 was observed under the hypoxic 
condition in vitro [30]. 
Direct causality between inflammation and prostate en-
largement is not evident. But, the T cell activity and asso-
ciated autoimmune reaction seem to induce epithelial and 
stromal cell proliferation.
4. Epithelial-stromal cell interaction and growth factor
In the normal state of the prostate, epithelial cells and stro-
mal cells are very closely associated. Through this inter-
action between these cells, homeostasis of growth and re-
gression of the prostate can be maintained. A variety of 
growth factors, such as epidermal growth factor (EFG), 
TGF-α, TGF-β, and basic FGF (bFGF), are involved as facil-
itators in the epithelial-stromal interaction [33]. 
EGF and TGF-α are the most powerful mitosis-promot-
ing factors for epithelial cells. Prostate tissue and prostate 
fluid include a lot of EGF. The promoting effect of the an-
drogen is thought to be mediated by the EGF, but it is not 
clear which cells produce EGF or TGF-α.
TGF β has various biological characteristics and is in-
creased in BPH. TGF-β inhibits the function of epithelial 
cells and is involved in growth arrest and apoptosis. The 
effect of TGF-β for matrix cells is unclear but it seems to 
engage the differentiation of matrix cells to the smooth cell 
phenotype or a variation of extramatrix cells [34]. TGF-β 
is distributed in smooth muscle actin-positive cells under 
immunohistochemistry stain. Thus, the origin of TGF-β is 
thought to be smooth muscle cells.
Basic FGF is a strong promoting factor of cellular mitosis 
and is over-expressed in BPH. In animal experiments, the 
over-production of bFGF results in glandular proliferation 
resembling significant clinical prostatic hyperplasia. 
Under normal conditions, bFGF is produced by both epi-
thelial and stromal cells, but even though the bFGF is emit-
ted out of cells, bFGF is locked up within the extracellular 
matrix. The function of bFGF in target cells may be one of 
the most important factors in understanding the etiology 
of BPH. The imbalance of these growth factors is accepted 
as the reason for the abnormal prostate growth.
5. Androgen receptor
The growth of the prostate is dependent on circulating an-
drogen and the intracellular steroid signaling pathway via 
androgen receptor. The transactivation of the androgen re-
ceptor is found in the transactivation domain encoded by 
exon 1 of the AR gene (Xq11-12), which contains poly-
morphic CAG and GGN (also GGC) repeats encoding poly-
glutamine and polyglycine tracts, respectively [35]. It is 
still unclear whether polymorphism of the androgen re-
ceptor affects proliferation of the prostate [36]. Some stud-
ies have reported that reduced CAG or GGN repeats in the 
AR gene are positively correlated with larger prostate size, 
whereas recent studies reached the opposite conclusion 
[36-38]. Given the significant variation in reported find-
ings, CAG or GGN polymorphism of the AR gene may not 
play a major role in the progression of BPH [39].
CLINICAL APPROACH
BPH-related LUTS can be treated by surgical and medical 
therapy, and the choice of treatment is based on the se-
verity of disease, risk of progression, and patient morbi-
dity. Various surgical and medical treatment options are 
available to improve LUTS in BPH patients (Table 1). 
Recently, the dynamic component of BPH has been empha-
sized, with a focus on symptoms rather than prostate en-
largement, which has led to a shift from surgery to medical 
treatment. However, the efficacy of pharmacotherapy re-
mains somewhat limited. Many minimally invasive surgi-
cal treatments, such as laparoscopic surgery and laser sur-
gery, have been developed, but controversy remains over 
whether these minimally invasive surgical treatments are Korean J Urol 2012;53:139-148
142 You and Cho
TABLE 2. Selectivity of α-adrenergic blockers to AR subtypes
Alfuzosin Doxazosin Tamsulosin Terazosin Silodosin Naftopidil
Selectivity to AR 
subtypes
Nonselective Nonselective α1A=α1D＞α1B Nonselective α1A＞α1D＞α1B α1D＞α1A＞α1B
AR, alpha-adrenergic receptor.
alternatives for TURP as the gold standard treatment.
1. Alpha-adrenergic blockers 
Quick and excellent efficacy without significant adverse ef-
fects has made the alpha-adrenergic antagonists, includ-
ing alzusosin, doxazosin, tamsulosin, and terazosin, the 
first-line therapy of BPH-related LUTS. Although minor 
differences in adverse effects between these drugs have 
been presented, their efficacy in reducing LUTS is compa-
rable. Alpha-adrenergic receptors (ARs) are distributed in 
the smooth muscle of the whole body. To date, four unique 
α1-AR subtypes (α1A, α1B, α1D, and α1L) have been iden-
tified, but the role of the α1L subtype has yet to be estab-
lished [40,41]. α1A-AR subtypes are predominant in hu-
man prostate and urethra. Distributions ratios of the 
α1A-AR and α1D-AR subtypes are 69.3% and 27.3% in the 
urethra and 85% and 15% in prostatic tissue, respectively 
[42,43]. The α1D-AR subtype is mainly expressed in the de-
trusor muscle of the bladder and the sacral region of the spi-
nal cord, and blockade of the α1D-AR subtype can relieve 
irritative symptoms [40,44].
Silodosin is a selective α1A-AR antagonist and its affin-
ity to the α1A-AR subtype is 583-fold that to the α1B-AR 
and 56-fold that to the α1D-AR. The affinity of tamsulosin 
to the α1-AR subtype is higher than that of silodosin but 
the affinity of tamsulosin to the α1A-AR subtype is 15 fold 
that to the α1B-AR and 3-fold that to the α1D-AR; thus, the 
selectivity of silodosin to α1A-AR is greater than that of 
tamsulosin [45]. The selectivity of alpha-adrenergic block-
ers to the subtypes of ARs is summarized in Table 2.
In a randomized, double-blind, active- and placebo-con-
trolled phase III study, 457 patients were divided into 3 
groups (silodosin, n=176; tamsulosin, n=192; placebo, 
n=89). Silodosin 4 mg PO BID, tamsulosin 0.2 mg PO once 
daily, or placebo were administered for 12 weeks. The total 
International Prostate Symptom Score (IPSS) and max-
imal uroflow rate (Qmax) in the silodosin and tamsulosin 
groups were improved significantly. The mean intergroup 
differences in total IPSS and Qmax between the silodosin 
and tamsulosin groups were not significant, and reduction 
of the voiding symptom score in the silodosin group was su-
perior to that in the tamsulosin group. Adverse effects oc-
curred more frequently in the silodosin group than in the 
tamsulosin group. The most common adverse effect in the 
silodosin group was ejaculatory disorders (22.3%) such as 
retrograde ejaculation, compared with 1.6% in the tamsu-
losin group [46]. These ejaculatory disorders were caused 
by smooth muscle relaxation in the bladder neck and vas 
deferens [47,48]. The high selectivity of silodosin to the 
α1A-AR is a distinguishing feature of this agent compared 
with other AR antagonists, but to prove the significant clin-
ical differences caused by the pharmacologic features of si-
lodosin, further large-scale study is needed.
Naftopidil is an α1D-AR subtype-selective antagonist. 
Whereas the affinity of tamsulosin and silodosin to the 
α1A-AR subtype is 3-fold and 56-fold that to the α1D-AR, 
the affinity of naftopidil to the α1D-AR subtype is 3-fold 
that to the α1A-AR subtype [49]. In comparative crossover 
studies between tamsulosin 0.2 mg and naftopidil 50 mg, 
both AR antagonists reduced the total IPSS and no inter-
group differences were identified. In the naftopidil group, 
however, storage symptoms such as daytime frequency, ur-
gency, and especially nocturia were improved more than 
in the tamsulosin group [50,51], and the mean first desire 
to void and mean maximum desire to void were sig-
nificantly higher than in the tamsulosin group (188.4 ml 
vs. 339.4 ml) [51]. In other studies, no data about irritative 
symptom improvement were reported. Additional study is 
needed to make solid conclusions. 
2. 5-Alpha-reductase inhibitor
5α-Reductase converts testosterone to dihydrotestoster-
one (DHT), which is more potent than testosterone in the 
prostate. 5α-Reductase inhibitor (5-ARI) acts as an an-
drogen suppressor causing regression of epithelial ele-
ments in the prostate. Consequently, prostatic enlarge-
ment, the static component of bladder outlet obstruction, 
is diminished. Finasteride (a type 2 5-ARI) and dutasteride 
(a dual inhibitor of both type 1 and type 2 5α-reductase) de-
crease the DHT level in the prostate by 80% and 94%, re-
spectively, and the serum half-life of finasteride is 6 to 8 
hours and that of dutasteride is 5 weeks [52,53]. This phar-
macologic discrepancy between these drugs makes a minor 
difference in efficacy and adverse effects.
In the Medical Therapy of Prostatic Symptoms Trial that 
compared monotherapy and combination therapy with 
doxazosin and finasteride, combination therapy lowered 
the risk of BPH progression compared with monotherapy 
with doxazosin or finasteride (67% for combination ther-
apy, 39% for doxazosin, 34% for finasteride) and was supe-
rior in improving the American Urological Association 
Symptom Index score and Qmax compared with mono-
therapy and placebo [54]. According to the Combination of 
Dutasteride and Tamsulosin study, which enrolled 4,844 
men ≥50 years of age with prostate volume ≥30 g and a 
clinical diagnosis of BPH, combination therapy reduced 
the relative risk of clinical progression, the risk of acute uri-
nary retention, and BPH-related surgery significantly and Korean J Urol 2012;53:139-148
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TABLE 3. Changes from baseline to 12 weeks in IPSS and IIEF in tadalafil treatment groups 
Improvement of symptoms Placebo
Tadalafil (mg)
2.5 5 10 20
Total IPSS
Irritative symptoms
Obstructive symptoms
QoL
IIEF-EF
2.27±0.49
0.99±0.23
1.26±0.33
0.49±0.11
2.20±1.03
3.88±0.5
1.58±0.23
2.23±0.33
0.74±0.11
5.59±1.01
a
4.87±0.49
a
1.89±0.23
a
2.94±0.33
a
0.86±0.11
a
6.97±1.01
a
5.17±0.49
a
1.96±0.23
a
3.13±0.32
a
0.92±0.10
a
7.98±1.0
a
5.21±0.5
a
2.07±0.23
a
3.12±0.33
a
0.88±0.11
a
8.34±1.01
a
Roehrborn et al., 2008 (J Urol 2008;180:1228-34). 
Values are presented mean±SD.
IPSS, International Prostate Symptom Score; QoL, quality of life; IEEF-EF, International Index of Erectile Function-Erectile Function
domain.
a: p-value＜0.05 compared with placebo.
induced greater symptom benefit than either monotherapy 
at 4 years [55]. Guidelines for the management of BPH by 
the American Urological Association and the European 
Association of Urology recommend the use of 5-ARIs for 
male patients with LUTS caused by an enlarged prostate.
3. Phosphodiesterase 5 inhibitor
There has been increasing interest in the use of phospho-
diesterase type-5 (PDE5) inhibitors to treat BPH-related 
LUTS. The current postulated mechanisms of action of 
PDE5 inhibitors in improving BPH-related LUTS include 
the following. First, inactivation of cGMP-mediated ρ-kin-
ase; second, increase of nitric oxide synthase (NOS) and NO 
activity in the prostate; third, decrease of autonomic hyper-
activity affecting the bladder, prostate, and penis; and 
fourth, reduction of pelvic ischemia [56,57]. Activated 
ρ-kinase inhibits smooth muscle myosin phosphatase. 
This action leads to the sensitization of myofilaments to 
Ca
2+, which results in smooth muscle contraction [58]. 
Increased NO and cGMP by PDE5 inhibitors relaxes the 
smooth muscles of the lower urinary tract and could be used 
for the treatment of LUTS [59]. Autonomic hyperactivity, 
an aspect of MetS, promotes contraction of the endothelium 
and ultimately could lead to the occurrence of LUTS [60]. 
Chronic ischemia and arterial insufficiency caused by 
bladder and penile atherosclerosis promote structural and 
functional changes of the bladder, prostate, and penis that 
also lead to LUTS [61].
In a study by McVary et al. [62], male patients with BPH 
and erectile dysfunction were administered 50 to 100 mg 
sildenafil and placebo daily for 12 weeks. Compared with 
that in the control group, IPSS and QoL in the sildenafil 
group were reduced (IPSS, 6.32 vs. 1.93 points; QoL, 0.97 
vs. 0.29 for sildenafil and placebo; p＜0.0001). In another 
study, 2.5, 5, 10, or 20 mg tadalafil was administered to 
BPH patients daily for 12 weeks. Except for the 2.5 mg tada-
lafil group, all other tadalafil groups improved signifi-
cantly in terms of IPSS and QoL compared with the placebo 
group. Also, 5 mg tadalafil showed the most superior 
risk-benefit profile. The mean IPSS reductions were 4.87 
for tadalafil 5 mg and 2.27 for the placebo group (p＜0.001). 
The mean improvements in the International Index of 
Erectile Function-Erectile Function domain score in the ta-
dalafil groups were superior to that in the placebo group 
(6.97 for tadalafil vs. 2.20 for placebo, p＜0.001) (Table 3) 
[63]. In a randomized, placebo-controlled study to assess 
the efficacy of twice-daily vardenafil 10 mg for 8 weeks, the 
mean IPSS reduction was significant in the vardenafil 
group compared with placebo (5.9 for vardenafil vs. 3.6 for 
placebo, p=0.0013). However, no significant difference in 
Qmax was found between the groups [64]. These preclinical 
and clinical studies have provided hopeful evidence that 
PDE5 inhibitors may be an effective and acceptable treat-
ment option for BPH, but at the present time, the high cost 
of PDE5 inhibitors is a significant obstacle. Cost-efficacy 
analysis must be conducted. 
4. Phytotherapy
Many kinds of complementary and alternative medicines 
have been used as treatment methods for BPH, and herbal 
therapy is considered to be the mainstay among those 
treatments [65]. Millions of people worldwide have used 
herbal agents to treat BPH-related LUTS, and recently, in-
terest in these agents has increased through advertise-
ments in the mass media and online shopping. Saw palmet-
to, one of the most popular herbal medicines, is an extract 
of the fruit of Serenoa repens composed of fatty acids and 
phytosterols. In a past meta-analysis, saw palmetto was 
shown to increase self-rated improvement, increase the 
peak flow rate, and in particular improve nocturia, but con-
troversy over its effects remain [66]. 
The mechanism of the effect of saw palmetto is poorly 
defined. Investigators have proposed antiandrogenic ac-
tivity via 5-alpha reductase inhibition and subsequent pre-
vention of the conversion of testosterone to dihydrotesto-
sterone [67], an anti-inflammatory effect [68], competitive 
inhibition of androgen binding, a decrease in the bioavail-
ability of the sex hormone-binding globulin [69], and in-
hibition of growth factor-induced prostatic cell prolifera-
tion [68,70].
In 2011, a double-blind, multicenter, placebo-controlled 
randomized study to investigate the efficacy of saw palmet-Korean J Urol 2012;53:139-148
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TABLE 4. Intraoperative and early postoperative complications of TURP
Mebust et al. (1989) [76]
(n=3,885)
Borboroglu et al. (1999) [77] 
(n=520)
Reich et al. (2008) [78] 
(n=10,654)
Transfusion (%)
TUR syndrome (%)
Urinary tract infection (%)
Voiding failure (%)
Mortality (%)
6.4
2.0
2.3
6.5
0.1
0.4
0.8
2.1
-
0
2.9
1.4
3.6
5.8
0.1
TURP, transurethral resection of the prostate.
to was reported [71]. Three hundred sixty-nine men ≥45 
years of age with Qmax≥4 ml/s and IPSS of 8 to 24 were 
enrolled and administered saw palmetto for 72 weeks. The 
dose of saw palmetto was 320 mg per day, which was esca-
lated to 960 mg per day if needed. Administration of saw 
palmetto had no significant effect in terms of IPSS, Qmax, 
or adverse effects compared with placebo.
5. Surgical therapy
Although the proportion of medical therapy and the use of 
several effective minimally invasive treatments have been 
increasing as a primary treatment for BPH, TURP remains 
the predominant treatment method [72]. TURP has been 
considered the gold standard treatment of BPH. Detection 
of prostate cancer in BPH patients with previously neg-
ative transrectal ultrasonography prostate biopsy is one of 
the advantages of TURP. Kim et al. [73] investigated 1,341 
BPH patients with a previous negative biopsy result who 
underwent TURP. They concluded that TURP could imme-
diately improve bladder outlet obstruction and provide an 
early diagnosis of clinically significant transition zone 
prostate cancer. Another study showed the excellent sur-
vival rate of patients with prostate cancer (stage pT1a) that 
was detected through TURP [74]. Deciding on a therapy in 
patients with mild LUTS, elevated prostate-specific anti-
gen (PSA) levels, and multiple negative previous biopsy re-
sults is a challenge for urologists. In these patients, bladder 
outlet obstruction may account for an elevated serum PSA 
level. TURP could improve LUTS without severe sur-
gery-related morbidity. Decreasing the level of serum PSA 
after TURP helps urologists to monitor prostate cancer de-
velopment by PSA [75].
Complications of TURP have been a challenging prob-
lem, but the rate of complications, including transurethral 
resection syndrome (TUR syndrome), postoperative bleed-
ing, and reoperation, has decreased. A cooperative study 
of 13 participating institutions evaluating 3,885 patients 
by Mebust et al. [76] that was published in 1989 reported 
a transfusion rate of 6.4%, an intraoperative complication 
rate of 6.0%, and a mortality rate of 0.1%. After a decade, 
Borboroglu et al. [77] reviewed 520 consecutive patients 
who underwent transurethral prostatectomy between 
1991 and 1998. They reported decreased immediate and 
postoperative complication rates (0.4% for transfusion, 
2.5% for intraoperative complications, and 0% for mortal-
ity). In the 2000s, Reich et al. [78] prospectively evaluated 
10,654 patients undergoing TURP in the state of Bavaria, 
Germany, from January 2002 until December 2003. This 
study reported intra- and perioperative morbidities as fol-
lows: transfusion rate 2.9%, TUR syndrome 1.4%, reopera-
tion 5.6%, and mortality 0.1% (Table 4). These advances in 
intra- and perioperative outcome have continued and the 
transfusion and reoperation rate are decreasing in patents 
who undergo TURP by an experienced surgeon.
One of the most outstanding technical advancements is 
the use of bipolar TURP. Bipolar devices allow TURP with 
saline irrigation, which lessens water intoxication and 
negates unwanted stimulation of the obturator nerves and 
cardiac devices. Bipolar TURP is an effective and safe sur-
gical treatment method with additional advantages over 
monopolar TURP, even in patients with large prostates. 
Vigorous complications including massive bleeding re-
quiring transfusion and TUR syndrome associated with bi-
polar TURP are rare [79,80].
Open simple prostatectomy can remove large prostate 
adenomas completely without complications like TUR syn-
drome, and reoperation caused by recurred prostate hyper-
plasia is extremely rare. However, massive hemorrhage 
and a long hospital stay were problematic. With the aim of 
addressing these complications and the disadvantages of 
both surgeries, in 2002, the first research on the efficacy 
and safety of laparoscopic simple prostatectomy was re-
ported [81]. In 2006, Baumert et al. [82] compared perioper-
ative outcomes of the first 30 consecutive laparoscopic sim-
ple prostatectomies performed by 1 surgeon and 30 consec-
utive open simple prostatectomies for patients with 
large-sized BPH of more than 100 g. The average operation 
time of laparoscopic surgery was longer than that for stand-
ard surgery but intraoperative blood loss (367±363 vs. 
643±647 ml), hospital stay (5.1±1.8 vs. 8±4.8 days), irriga-
tion time (0.33±0.7 vs. 4±3.5 days), and duration of catheter 
indwelling (4±1.7 vs. 6.8±4.7 days) were shorter in laparo-
scopic prostatectomy. Several other studies also reported 
significant improvement of IPSS and Qmax in patients 
with huge BPH by laparoscopic retropubic prostatectomy. 
No severe complications such as postoperative incon-
tinence were reported [83,84].
To reduce the disadvantages including postoperative 
bleeding, the long period of catheterization, and TUR syn-
drome, many kinds of laser surgery have been used, of Korean J Urol 2012;53:139-148
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which potassium-titanyl-phosphate laser vaporization of 
the prostate and Holmium laser enucleation of the prostate 
(HoLEP) are the most representative. Kang et al. [85] in-
vestigated the efficacy and complications of Greenlight 
HPS laser photo-selective vaporization of the prostate 
(PVP) in treating 104 BPH patients. Without delayed hem-
aturia, obstructive retention, or TUR syndrome, improve-
ment of IPSS and Qmax were maintained for at least 12 
months postoperatively. The only major postoperative 
complication in this study was mild dysuria (n=14, 13.4 %). 
Kim et al. [86] analyzed the clinical data of 74 patients who 
underwent PVP laser vaporization of the prostate with 2 
years of follow-up. IPSS and uroflowmetry with postvoid 
residual urine volume (PVR) were assessed at 1, 3, 6, 12, 
and 24 months postoperatively. Significant improvements 
at 1 month after surgery compared with baseline were 
maintained up to 24 months postoperatively. Although the 
safety and efficacy of PVP are brilliant, the need for addi-
tional laser fibers in dealing with large prostates and the 
loss of prostate tissues for pathologic testing are consid-
erable limits of PVP.
HoLEP can be used in treating patients with huge BPH 
without these problems. The holmium laser, with a wave-
length of 2,140 nm, conducts through saline and has ex-
cellent hemostatic properties. There is potentially no limit 
to the size of a prostate that can be treated with HoLEP. 
Krambeck et al. [87] reported significant improvement of 
IPSS (from 19 to 6.5 at 6 months postoperatively) and Qmax 
(from 8.2 ml/s to 18.5 ml/s at 6 months postoperatively) in 
treating patients with BPH (average size of prostate, 217 
g) without any severe complications. In another study that 
analyzed long-term operative outcomes of 164 consecutive 
HoLEP cases, the median PVR declined by 87.5%, whereas 
the mean Qmax rate was increased by 94% and the mean 
IPSS and median QoL scores were decreased by 63.2%, and 
56.6%, respectively, at 6 months postoperatively. Postope-
rative complications included transient incontinence 
(8.5%) and urinary retention (4.3%), and 3% of patients re-
quired readmission due to delayed hematuria [88]. The rel-
atively high occurrence rate of transient incontinence (1.4 
to 44%) is one of the most problematic complications in 
HoLEP [89-91]. The slow learning curve is also a challenge, 
and the operative time is still longer compared with stand-
ard TURP [90,92]. If technical advancements to reduce 
transient incontinence and operation times are developed, 
HoLEP can become the mainstay in treating patients with 
large BPH.
CONCLUSIONS
Benign prostatic hyperplasia is one of the most common 
problems that urologists deal with in the clinic. The preva-
lence of BPH increases from approximately 50% at 60 years 
of age to 90% in men older than 85 years. The etiologies of 
BPH are still not well defined. To date, multi-factorial and 
chronic conditions including metabolic syndrome, genet-
ics, inflammation, and lifestyle have been studied to pre-
vent BPH progression. Patients’ demands for effective, 
safe, and easy treatment options have led to several trials 
of medicine and minimally invasive surgeries such as laser 
or laparoscopic surgery. To date, admirable advancements 
in understanding the causes of BPH progression and in de-
veloping new gold standards of treatment have been 
achieved. However, unsolved problems remain in the pre-
clinical and clinical aspects of BPH.
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